Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Novartis Ag (NOVN.SW)
Novartis To Expand Community Health Programs To Over 30 Countries By 2030
4/9/2026 2:17:37 AM
Novartis Expands Health Programs To Tackle Heart Disease, Cancer In 30+ Nations By 2030
4/9/2026 1:59:33 AM
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS
4/3/2026 5:10:06 AM
Novartis: Fabhalta Cut Kidney Function Decline By 49.3% In IgAN
3/30/2026 7:06:37 AM
Novartis To Acquire Excellergy, Expanding Allergy Leadership
3/27/2026 8:41:15 AM
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
3/20/2026 10:13:56 AM
Novartis To Acquire SNV4818 In Up To $3 Bln Deal To Boost Breast Cancer Pipeline
3/20/2026 3:31:05 AM
Novartis To Buy Pikavation Therapeutics With PI3Ka Inhibitor From Synnovation For $2 Bln Upfront
3/20/2026 2:55:28 AM
Novartis Gains FDA Approval For Cosentyx In Pediatric Hidradenitis Suppurativa
3/16/2026 3:17:07 AM
Novartis: Pluvicto Shows Effectiveness In Real-world Studies
2/24/2026 8:35:58 AM
Novartis Unveils Real-World Data That Reinforce Earlier Use Of Pluvicto Before Chemotherapy In MCRPC
2/24/2026 8:03:41 AM
Novartis Presents 5 Key Abstracts Evaluating Rhapsido In CSU, Peanut Allergy At AAAAI Annual Meet
2/23/2026 5:23:40 AM
Novartis Presents Phase II Remibrutinib Data In IgE-mediated Peanut Allergy At AAAAI
2/23/2026 1:21:08 AM
Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020
2/20/2026 9:27:44 AM
Novartis' Phase 3 Trial Of Remibrutinib Meets Primary Endpoint In Chronic Inducible Urticaria
2/18/2026 5:12:02 AM
Novartis's Remibrutinib Meets Primary Goals In Phase 3 RemIND Trial Across Three Variants Of CIndu
2/18/2026 4:23:30 AM
Novartis Reports Positive Data From Phase III ALIGN Study For Vanrafia In IgA Nephropathy
2/13/2026 4:39:09 AM
Novartis Reports Positive Data From Phase III ALIGN Study For Vanrafia In IgA Nephropathy
2/13/2026 2:49:37 AM
Novartis Q4 Profit Down, Sales Rise; Sees Higher Sales In FY26
2/4/2026 1:13:31 AM
Novartis AG Q4 Profit Falls
2/4/2026 1:09:00 AM
1
2
Next
»